Overview

Intravenous Allopurinol in Heart Failure

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Allopurinol